AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04671771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnAVasc Arteriovenous Graft (IG) surgical implant
Description: The InnAVasc Arteriovenous Graft (IG) is a hemodialysis vascular access graft, intended for implantation in the lower or upper arm using standard vascular techniques, in patients requiring hemodialysis
Study NCT02102620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular injection with corticosteroid
Description: After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
Study NCT05840848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control beta-carotene supplement plus Placebo
Description: 15 mg beta-carotene supplement from BIOVEA consumed before breakfast together with an empty capsule.
Study NCT05840848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control beta-carotene supplement plus iron Supplement
Description: 15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
Study NCT05840848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control beta-carotene supplement plus zinc Supplement
Description: 15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 30 mg zinc (ZnSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
Study NCT04044222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: IV
Study NCT04044222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV
Study NCT04044222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV
Study NCT04044222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: IV
Study NCT04044222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV
Study NCT00394355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate dry powder inhaler
Description: 400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
Study NCT00394355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate dry powder inhaler
Description: 200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
Study NCT02102620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular injection with lidocaine
Description: After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
Study NCT03014895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg MK-0517 (non-PS80)
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
Study NCT00394355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate hydrofluoroalkane (HFA)
Description: 250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
Study NCT00394355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: 10 mg given once daily in the evening by mouth for 1 year.
Study NCT03094312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Spectral Imaging (ISD)
Description: cerebral stimulation: dynamic spectral imaging (ISD)
Study NCT00424125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Pharmacy Care
Description: Participants randomized to Enhanced Pharmacy Care will have their prescriptions electronically transmitted or faxed to one of the five participating pharmacies.~Pharmacists will then provide real-time, targeted education around the purpose and use of the new and refilled ICS medications to study participants and their families at each point of contact, including rationale for their use, device teaching, dosage review, and importance of compliance. Families randomized to enhanced care will also be contacted monthly by phone and mail with reminders to fill their controller medications prescriptions and to seek ongoing longitudinal asthma care with their primary care providers.
Study NCT00424125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual care.
Study NCT02612064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride dentifice
Description: Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
Study NCT02612064 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sodium Monofluorophosphate dentifrice
Description: Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
Study NCT03852043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: The intervals of high intensity are conducted between 90 and 95 % of heart rate maximum (HRmax) and resting between 50 and 60 % of the HRmax 15 loads of 30 seconds at high intensity, with 60 seconds of recovery at loads of moderate intensity.
Study NCT03852043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity continuous training
Description: The continuous training will be carried out at an intensity between 65 and 75% of the HRmax.
Study NCT02249455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella
Description: Treatment time for 20 min twice daily
Study NCT02249455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELTGOL
Description: ELTGOL technique 20 min twice daily
Study NCT02249455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Conventional physiotherapy was given twice daily for 20 min
Study NCT01188109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care chemotherapy and dosage~Dose - 1000 mg/m²~Schedule - Days 1 and 15; Q 28 days
Study NCT01188109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose - 50 mg/m²~Schedule - Days 1 and 15; Q 28 days
Study NCT04065503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic Strains
Description: A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.
Study NCT02930473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIC Psychotherapeutic Intervention(s) for Anxiety
Description: Patients will be treated by NIC psychotherapeutic intervention(s) for anxiety (e.g. anxiety reduction) plus psychopharmaceuticals prescribed by their psychiatrist.
Study NCT02930473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychopharmaceuticals (any drugs prescribed by the psychiatrist)
Description: Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
Study NCT02930473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psychopharmaceuticals (any drugs prescribed by the psychiatrist)
Description: Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg MK-0517 (non-PS80)
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg MK-0517 (Non-PS80)
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching MK-0517
Study NCT03014895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg Aprepitant
Description: Aprepitant, oral, tablet, single dose
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose
Study NCT03778034 — intervention group
Intervention type: OTHER
Intervention: female with Forward head posture
Description: measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
Study NCT03778034 — intervention group
Intervention type: OTHER
Intervention: healthy female without (FHP)
Description: measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
Study NCT01743950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 10mg/kg every 2weeks.
Study NCT02792894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family networks program
Description: Intervention, Family networks Program (FaNs), is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO parent skills training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
Study NCT02960035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg etanercept
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
Study NCT00990821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg Midazolam
Description: Midazolam oral tablet, single dose
Study NCT01095809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol
Study NCT01095809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: 2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
Study NCT01702155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP-10917
Study NCT01801813 — intervention group
Intervention type: OTHER
Intervention: Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications
Study NCT01568112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 (dimethyl fumarate)
Description: Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
Study NCT01568112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 placebo
Description: Placebo matching BG00012
Study NCT01568112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BG00012 placebo
Description: Placebo matching BG00012
Study NCT01568112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: 325 mg microcoated aspirin (ASA)
Study NCT01568112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA placebo
Description: Placebo matching aspirin
Study NCT01568112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASA placebo
Description: Placebo matching aspirin
Study NCT02756299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Support
Description: General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
Study NCT02756299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Support
Description: General information about OSA and PAP treatment at baseline
Study NCT04063878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conometric Abutment and Conometric Final Cap
Description: Conometric concept developed by Dentsply Sirona Implants for implant systems Ankylos, Astra Tech Implant System and Xive.
Study NCT01601639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Band Ligation
Description: Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
Study NCT01601639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon plasma Coagulation (APC) for GAVE
Description: APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
Study NCT03514745 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope
Description: Endobronchial intubation is performed using the GlideScope.
Study NCT03514745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lighted stylet
Description: Endobronchial intubation is performed using a lighted stylet.
Study NCT04999683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ITIS diet
Description: anti-inflammatory diet for 14 days
Study NCT02046057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PNB of SLN
Description: Percutaneous biopsy of sentinel node
Study NCT00650156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 80 mg single sc dose
Study NCT03513354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soil group
Description: Exercises in soil.
Study NCT03513354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pool group
Description: Exercises in pool.
Study NCT03674710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard suction, slow-pull, wet suction
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.
Study NCT03674710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard suction, wet suction, slow-pull
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.
Study NCT03674710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow-pull, standard suction, wet suction
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.
Study NCT03674710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow-pull, wet suction, standard suction
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.
Study NCT02960035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg etanercept
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
Study NCT01743950 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PRDR
Description: Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
Study NCT02960035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02648282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg/m2 as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 6 months for an additional 4 doses.
Study NCT02648282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX Pancreatic Cancer Vaccine
Description: 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of 8 doses. In the extended treatment phase, eligible patients may receive 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells administered one day after CY every 6 months for an additional 4 doses.
Study NCT02648282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg as a 30 minute IV infusion every 21 days for an additional 9 doses.
Study NCT02648282 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX Pancreas Vaccine).
Study NCT00582686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF of Calcaneus without bone grafting
Description: The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
Study NCT03214094 — intervention group
Intervention type: DRUG
Intervention: Vonoprazan
Description: Vonoprazan tablets
Study NCT04061538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: zinc 20mg tablets
Study NCT04061538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic zinc 20mg tablet
Study NCT02711111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face mask
Description: to apply for on the upper jaw (12 - 14 hrs / day) via extra-oral elastics to the face mask
Study NCT02711111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic bone anchor
Description: to apply force on the upper jaw (24 / 7) via intra-oral elastics on the bone-anchor
Study NCT02527343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volanesorsen
Description: 300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).
Study NCT02527343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Volanesorsen-matching placebo administered SC injection.
Study NCT01029652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Description: Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
Study NCT01029652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide 40 mg
Description: Triamcinolone acetonide 40 mg was supplied as a suspension.
Study NCT01029652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to canakinumab
Description: Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
Study NCT01029652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to triamcinolone acetonide
Description: Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
Study NCT01419457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1200 mg BID for Day 1 + 800 mg BID for Day 2-5
Study NCT01419457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 800 mg BID for Day 1 + 400 mg BID for Day 2-3
Study NCT03674710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet suction, standard suction, slow-pull
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.
Study NCT03674710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet suction, slow-pull, standard suction
Description: Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence.
Study NCT02959775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg dose hepatitis B vaccine
Description: three-dose, 60 µg per dose